Drug Interaction Report
4 potential interactions and/or warnings found for the following 2 drugs:
- trospium / xanomeline
- dofetilide
Interactions between your drugs
dofetilide trospium
Applies to: dofetilide, trospium / xanomeline
MONITOR: The major pathway for elimination of dofetilide is through glomerular filtration and active tubular secretion using the cation transport system. Competition for this elimination pathway by other drugs may potentially result in increased levels of dofetilide and increase the risk of QT interval prolongation and ventricular arrhythmias. The clinician should be aware of the potential for an interaction when dofetilide is used in combination with another medication that is excreted via this pathway.
MANAGEMENT: The manufacturer recommends that the patient be closely monitored if these drugs are coadministered.
References (1)
- (2001) "Product Information. Tikosyn (dofetilide)." Pfizer U.S. Pharmaceuticals
dofetilide xanomeline
Applies to: dofetilide, trospium / xanomeline
MONITOR: Xanomeline may increase the concentration of sensitive oral CYP450 3A4 substrates and/or narrow therapeutic index (NTI) oral P-glycoprotein (P-gp) substrates. In vitro data suggest that xanomeline may transiently inhibit CYP450 3A4 and P-gp locally in the intestine after dosing. Xanomeline does not appear to inhibit CYP450 3A4 and/or P-gp systemically. Clinical data evaluating this interaction are not available.
MANAGEMENT: Caution and clinical monitoring are advised if xanomeline is used in combination with an orally administered CYP450 3A4 sensitive substrate and/or NTI P-gp substrate for which a small change in substrate plasma concentration could lead to serious toxicities. The labeling of the substrate may be consulted for specific monitoring and dose adjustment recommendations should adverse reactions result from this combination.
References (1)
- (2024) "Product Information. Cobenfy (trospium-xanomeline)." Bristol-Myers Squibb
Drug and food interactions
trospium food
Applies to: trospium / xanomeline
ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of trospium chloride. According to the product labeling, administration of trospium chloride with a high fat meal reduced the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 70% to 80% compared to administration while fasting.
MANAGEMENT: To ensure maximal oral absorption, trospium chloride should be administered at least 1 hour before meals or on an empty stomach. If trospium chloride is administered as a combination with xanomeline, the manufacturer recommends administering the capsules at least 1 hour before a meal or at least 2 hours after a meal. Capsules should be taken whole.
References (5)
- (2012) "Product Information. Sanctura (trospium)." Odyssey Pharmaceuticals
- (2024) "Product Information. Cobenfy (trospium-xanomeline)." Bristol-Myers Squibb
- (2019) "Product Information. Trosec (trospium)." Oryx Pharmaceuticals Inc
- (2022) "Product Information. Regurin (trospium)." Mylan Healthcare Sdn. Bhd.
- (2023) "Product Information. Trospium Chloride (trospium)." Padagis
dofetilide food
Applies to: dofetilide
In vitro data suggest that grapefruit juice may inhibit the CYP450 3A4 first-pass metabolism of dofetilide. Decreased first-pass metabolism may increase dofetilide concentrations and increase the risk of QT interval prolongation and arrhythmias. The clinical significance is unknown, since dofetilide has a high oral bioavailability and a low affinity for CYP450 3A4. The manufacturer recommends caution.
References (1)
- (2001) "Product Information. Tikosyn (dofetilide)." Pfizer U.S. Pharmaceuticals
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Rexulti
Rexulti (brexpiprazole) is a prescription antipsychotic medication used in the treatment of major ...
Vraylar
Vraylar is a once a day antipsychotic medication used to treat mental health or mood disorders ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Abilify
Abilify is an antipsychotic medicine used to treat the symptoms of schizophrenia and bipolar ...
Seroquel
Seroquel is used to treat the symptoms of schizophrenia, bipolar disorder and major depressive ...
Zyprexa
Zyprexa (olanzapine) is an atypical antipsychotic that may be used to treat adults and adolescents ...
Latuda
Latuda information from Drugs.com, includes Latuda side effects, interactions and indications.
Risperdal
Risperdal is used to treat schizophrenia and symptoms of bipolar disorder. Learn about side ...
Caplyta
Caplyta (lumateperone) may be used to treat schizophrenia or depression associated with bipolar ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.